Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2018 – ResearchByMarkets

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2018, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue. 

Report Highlights

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 4, 7, 2, 45, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST A SAMPLE REPORT:
https://www.researchbymarkets.com/sample-request/41674

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
– The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
– The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Buy this report via Credit Card/Paypal or Wire Transfer:
https://www.researchbymarkets.com/paynow/41674

Companies Mentioned: 
Aeolus Pharmaceuticals Inc
Angion Biomedica Corp
Atox Bio Ltd
BCN Biosciences LLC
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Cellphire Inc
Chrysalis BioTherapeutics Inc
Cleveland BioLabs Inc
Consegna Pharma Inc
Daiichi Sankyo Co Ltd
FirstString Research Inc
Galera Therapeutics Inc
GNI Group Ltd
Humanetics Corp
iNtRON Biotechnology Inc
Meabco AS
Medesis Pharma SA
Neumedicines Inc
Nohla Therapeutics Inc
Onconova Therapeutics Inc
Original BioMedicals Co Ltd
P2D Inc
PharmaIN Corp
Pluristem Therapeutics Inc
RDD Pharma Ltd
RedHill Biopharma Ltd
RxBio Inc
SK Chemicals Co Ltd
Soligenix Inc
Synedgen Inc
Therapeutic Systems Research Laboratories Inc
Tonix Pharmaceuticals Holding Corp
Windtree Therapeutics Inc

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.